Real-World Case Series of Omidubicel-Onlv for Allogeneic Transplantation in Patients with Hematologic Malignancies Using a Reduced Toxicity Myeloablative Conditioning Regimen

Key Points

• Omidubicel shows potential for improving outcomes after allogeneic transplantation in patients with hematologic malignancies.
• The study highlights the use of a reduced toxicity myeloablative conditioning regimen that may enhance recovery.
• Analysis includes data from multiple cases, indicating promising efficacy and tolerability of the intervention.
• These findings support the need for further studies on omidubicel's role in transplantation protocols.